GT Biopharma, Inc.
GTBP
$0.42
-$0.01-1.69%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -30.41M | -28.35M | -9.10M | -9.40M | -11.67M |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 16.52M | 16.36M | -935.00K | -1.18M | -139.00K |
| Change in Net Operating Assets | 713.00K | -920.00K | -1.33M | 149.00K | 868.00K |
| Cash from Operations | -13.18M | -12.91M | -11.36M | -10.42M | -10.94M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | 1.00K | 0.00 | 7.86M |
| Cash from Investing | -- | -- | 1.00K | 0.00 | 7.86M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 5.46M | 5.50M | 1.05M | 1.05M | 3.59M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | 14.51M | 10.51M | 6.50M | 5.44M | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -229.00K | -229.00K | -85.00K | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 19.74M | 15.78M | 7.47M | 6.49M | 3.59M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 6.56M | 2.86M | -3.89M | -3.93M | 508.00K |